DBV Technologies SA (NASDAQ:DBVT – Get Rating) has been assigned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat reports. One equity research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12-month price target among brokers who have covered the stock in the last year is $6.67.
A number of analysts have recently weighed in on DBVT shares. JMP Securities reissued a “market outperform” rating and issued a $4.00 price objective on shares of DBV Technologies in a research report on Friday, March 3rd. StockNews.com started coverage on DBV Technologies in a research report on Sunday, June 18th. They issued a “sell” rating for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of DBV Technologies in a research report on Friday, March 3rd.
DBV Technologies Trading Down 7.3 %
DBVT opened at $2.03 on Friday. The firm has a market cap of $382.20 million, a price-to-earnings ratio of -3.33 and a beta of 1.26. DBV Technologies has a 12 month low of $1.08 and a 12 month high of $2.94. The stock has a fifty-day moving average price of $1.82 and a 200-day moving average price of $1.60.
DBV Technologies (NASDAQ:DBVT – Get Rating) last issued its quarterly earnings data on Thursday, May 4th. The company reported earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.14. DBV Technologies had a negative net margin of 778.60% and a negative return on equity of 48.25%. The firm had revenue of $2.19 million for the quarter, compared to the consensus estimate of $1.30 million. On average, equity research analysts forecast that DBV Technologies will post -0.51 EPS for the current year.
Institutional Investors Weigh In On DBV Technologies
A number of large investors have recently bought and sold shares of the company. OLD Mission Capital LLC boosted its position in DBV Technologies by 243.7% in the first quarter. OLD Mission Capital LLC now owns 30,597 shares of the company’s stock valued at $52,000 after buying an additional 21,694 shares during the last quarter. Jane Street Group LLC acquired a new position in DBV Technologies during the fourth quarter valued at $54,000. Millennium Management LLC lifted its position in DBV Technologies by 53.9% during the fourth quarter. Millennium Management LLC now owns 871,996 shares of the company’s stock valued at $1,334,000 after purchasing an additional 305,562 shares during the period. Braidwell LP acquired a new position in DBV Technologies during the fourth quarter valued at $18,525,000. Finally, VR Adviser LLC acquired a new position in DBV Technologies during the fourth quarter valued at $29,258,000. Hedge funds and other institutional investors own 22.43% of the company’s stock.
DBV Technologies Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed a Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk which is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow’s milk protein allergy (CMPA) and eosinophilic esophagitis.
Receive News & Ratings for DBV Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DBV Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.